A M Marra1, M Arcopinto2, E Bossone3, N Ehlken4, A Cittadini5, E Grünig4. 1. Pulmonary Hypertension Unit, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany; Department of Translational Medical Sciences, "Federico II" University School of Medicine, Naples, Italy. 2. Department of Cardiac Surgery, IRCSS Policlinico San Donato, Milan, Italy. 3. Department of Cardiology and Cardiac Surgery, University Hospital "Scuola Medica Salernitana", Salerno, Italy. 4. Pulmonary Hypertension Unit, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany. 5. Department of Translational Medical Sciences, "Federico II" University School of Medicine, Naples, Italy; Interdisciplinary Research Centre in Biomedical Materials (CRIB), Federico II University, Naples, Italy. Electronic address: cittadin@unina.it.
Abstract
BACKGROUND AND AIM: Exercise intolerance is one of the key features of pulmonary arterial hypertension (PAH). The main determinants of exercise impairment include hypoxemia, reduced right ventricular output, perfusion/ventilation mismatch, and weakness of skeletal and breathing muscles. The aim of the current review is to describe the findings in the existing literature about respiratory and muscle dysfunction in PAH. Animal and clinical studies regarding both respiratory and peripheral skeletal muscles and the effect of exercise training on muscle function in PAH patients are analyzed. DATA SYNTHESIS: PAH myopathy is characterized by reduced skeletal muscle mass, reduced volitional and non-volitional contractility, reduced generated force, a fiber switch from type I to type II, increased protein degradation through ubiquitin-proteasome system (UPS) activation, reduced mitochondrial functioning, and impaired activation-contractility coupling. Increased inflammatory response, impaired anabolic signaling, hypoxemia, and abnormalities of mitochondrial function are involved in the pathophysiology of this process. Exercise training has been shown to improve exercise capacity, peak oxygen uptake, quality of life, and possibly clinical outcomes of PAH patients. CONCLUSIONS: The skeletal muscles of PAH patients show a wide spectrum of cellular abnormalities that finally culminate in muscle atrophy and reduced contractility. Exercise training improves muscle function and bears a positive impact on the clinical outcomes of PAH patients.
BACKGROUND AND AIM: Exercise intolerance is one of the key features of pulmonary arterial hypertension (PAH). The main determinants of exercise impairment include hypoxemia, reduced right ventricular output, perfusion/ventilation mismatch, and weakness of skeletal and breathing muscles. The aim of the current review is to describe the findings in the existing literature about respiratory and muscle dysfunction in PAH. Animal and clinical studies regarding both respiratory and peripheral skeletal muscles and the effect of exercise training on muscle function in PAH patients are analyzed. DATA SYNTHESIS: PAH myopathy is characterized by reduced skeletal muscle mass, reduced volitional and non-volitional contractility, reduced generated force, a fiber switch from type I to type II, increased protein degradation through ubiquitin-proteasome system (UPS) activation, reduced mitochondrial functioning, and impaired activation-contractility coupling. Increased inflammatory response, impaired anabolic signaling, hypoxemia, and abnormalities of mitochondrial function are involved in the pathophysiology of this process. Exercise training has been shown to improve exercise capacity, peak oxygen uptake, quality of life, and possibly clinical outcomes of PAH patients. CONCLUSIONS: The skeletal muscles of PAH patients show a wide spectrum of cellular abnormalities that finally culminate in muscle atrophy and reduced contractility. Exercise training improves muscle function and bears a positive impact on the clinical outcomes of PAH patients.
Authors: Dmitry A Goncharov; Elena A Goncharova; Stevan P Tofovic; Jian Hu; Jeff J Baust; Andressa Z Pena; Arnab Ray; Analise Rode; Rebecca R Vanderpool; Ana L Mora; Mark T Gladwin; Yen-Chun Lai Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405
Authors: Ahmad Sabbahi; Richard Severin; Cemal Ozemek; Shane A Phillips; Ross Arena Journal: Expert Rev Respir Med Date: 2020-01-03 Impact factor: 3.772
Authors: Michele Arcopinto; Andrea Salzano; Francesco Giallauria; Eduardo Bossone; Jörgen Isgaard; Alberto M Marra; Emanuele Bobbio; Olga Vriz; David N Åberg; Daniele Masarone; Amato De Paulis; Lavinia Saldamarco; Carlo Vigorito; Pietro Formisano; Massimo Niola; Francesco Perticone; Domenico Bonaduce; Luigi Saccà; Annamaria Colao; Antonio Cittadini Journal: PLoS One Date: 2017-01-17 Impact factor: 3.240
Authors: Manuel J Richter; Jan Grimminger; Britta Krüger; Hossein A Ghofrani; Frank C Mooren; Henning Gall; Christian Pilat; Karsten Krüger Journal: Pulm Circ Date: 2017-02-01 Impact factor: 3.017
Authors: Mehmet Toptas; Mazhar Yalcin; İbrahim Akkoc; Eren Demir; Cagatay Metin; Yildiray Savas; Muhsin Kalyoncuoglu; Mehmet Mustafa Can Journal: Biomed Res Int Date: 2018-02-12 Impact factor: 3.411